EXACT Therapeutics AS Announces Appointment of Dr Per Walday as Chief Executive Officer

OSLO/LONDON, 28 March 2022: EXACT Therapeutics AS (“EXACT-Tx”, Euronext Growth: EXTX), a clinical stage precision health company utilising Acoustic Cluster Therapy (ACT®) across multiple therapeutic areas, announces that its Board of Directors has today appointed Dr Per Walday as Chief Executive Officer (CEO).

A successful senior executive in the healthcare industry, Per has experience from research to commercialization of therapeutics and medical devices globally, including drug-device combination within the field of oncology. As CEO of PCI Biotech (OSE: PCIB), Per built an effective organization that progressed the platform technology into a pipeline of assets including in late stage clinical programs through FDA and EMA regulatory paths. Prior to this, Per spent almost two decades with Nycomed Imaging and GE Healthcare based in Norway where, as Global Head Project Management, he was responsible for all development programs of new pharmaceutical products. These included R&D efforts within the field of ultrasound and microbubbles which paved the way for what would become years later EXACT-Tx’s Acoustic Cluster Therapy (ACT®). Per has a six months’ notice period; start date with EXACT-Tx to be agreed.

Dr Masha Strømme, Executive Chair of the Board, commented: “The Board and I are very excited to welcome Per as CEO of EXACT-Tx:  He brings intimate knowledge of ultrasound along with therapeutic expertise and strong leadership. We are thrilled to have Per lead EXACT-Tx through the next phase of its development”.

Dr Per Walday, Chief Executive Officer-designate of EXACT-Tx, said: “I am very excited to be joining EXACT-Tx and very impressed by the potential of its proprietary technology. Remarkable innovation and progress have been made with the ACT® platform since I led the development of related ultrasound technology initially aimed for diagnostic use in GE Healthcare. The global ambitions and the potential of ACT® to meet current needs in both immuno-oncology and neurology harmonise well with my background and interests. I aim to further maximise the value of the innovative ACT® platform for ultrasound mediated drug enhancement and accelerate our journey towards becoming a leading precision health company.”